Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 06.03.2026
DOI: 10.1111/ddg.15996 ↗Kurz gefasst
Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, online erschienen am 06.03.2026. Verfasst von Magdalena Seidl-Philipp und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medical University of Innsbruck, Medizinische Universität Innsbruck.
Abstract (Originalsprache)
Background
Erythropoietic protoporphyria (EPP) is a rare genetic disorder characterized by severe phototoxic reactions that occur within minutes of light exposure. In clinical studies, afamelanotide has been shown to prolong pain‐free sun exposure, improve quality of life, and reduce the frequency and severity of phototoxic reactions.
Objective
To present the real‐world data of the Austrian EPP cohort treated with afamelanotide. Patients and Methods Data from all Austrian EPP patients treated with afamelanotide in 2023 (n = 20) were analyzed and compared to baseline data on quality of life, phototoxic burn tolerance time (PBTT), reported UV index on the day with the longest PBTT, and incidence and severity of phototoxic reactions.
Results
Before treatment, the EPP QoL score had a median of 11.11 (IQR 3.03–19.44) and increased to a median of 79.17 (IQR 75.00–97.22) under therapy. Phototoxic burn tolerance time (PBTT) increased from a median of 15 minutes (IQR 10–25) to a median of 250 minutes (IQR 120–300) under therapy. Before therapy 88% of patients had phototoxic reactions, while on therapy only 33% were affected. Treatment side effects were only mild and transient.
Conclusions
The real‐world data of the Austrian cohort confirm the effectiveness and safety of afamelanotide in EPP patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria.
- Department of Dermatology and Venereology, Medical University of Graz, Austria.
- Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Austria.
ORCID-Profile: Magdalena Seidl-Philipp, Gerold Schwantzer, Maximilian Lammer, Peter Wolf
Förderung
- Medical University of Innsbruck
- Medizinische Universität Innsbruck
Zitieren
APA
Seidl-Philipp, M., Schratter, H., Auer, J., Schwantzer, G., Lammer, M., Hinteregger, P., Vergeiner, I., Gruber, R., Wolf, P., & Hofer, A. (2026). Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15996
Vancouver
Seidl-Philipp M, Schratter H, Auer J, Schwantzer G, Lammer M, Hinteregger P, et al. Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2026. doi:10.1111/ddg.15996
BibTeX
@article{SeidlPhilipp2026,
author = {Seidl-Philipp, Magdalena and Schratter, Hanna and Auer, Johanna and Schwantzer, Gerold and Lammer, Maximilian and Hinteregger, Philipp and Vergeiner, Ines and Gruber, Robert and Wolf, Peter and Hofer, Angelika},
title = {Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2026},
doi = {10.1111/ddg.15996}
}
EUVIMED